In the month of April 2017 tenofovir alafenamide (TAF) tablets were added to the list of first-line therapies recommended for treating chronic hepatitis B (CHB). The tenofovir tablet comes with the Black Box Warning. Lactic acidosis and also severe hepatomegaly with steatosis, including fatal cases, have been noted with the use of tenofovir alafenamide. Discontinuation of anti-hepatitis B treatment or therapy may be responsible for resulting in severe acute exacerbations of hepatitis B. Monitor the hepatic function closely in such patients who discontinue Tenofovir Alafenamide (TAF).